

BIOINFORMANT

Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report



1ST AND ONLY MARKET RESEARCH FIRM TO
SPECIALIZE IN THE STEM CELL INDUSTRY

TABLE OF CONTENTS

1.	REPORT OVERVIEW	18
1.1	Statement of the Report.....	18
2.	INTRODUCTION	20
3.	CURRENT STATUS OF IPSC INDUSTRY	21
3.1	Approval of the First Two iPSC-based Therapies	21
3.1.1	Amchepry (raguneprocel)	21
3.1.2	ReHeart.....	22
3.2	Forthcoming iPSC-Derived Therapeutics	22
3.2.1	Fertilo	22
3.2.2	Bemdaneprocel (BRTX-100).....	23
3.3	The Second Line of iPSC-based Products in Clinical Trials.....	24
3.4	Current Status of iPSC-Based Clinical Trials for Therapeutic Development.....	24
3.5	AI-Powered Automation in iPSC Manufacturing.....	25
3.5.1	Companies Providing AI-Powered Automation Services.....	25
3.6	Advanced Reprogramming Technologies Currently in use	26
3.6.1	The Major Patent Cliff beginning in 2026.....	27
3.6.1.1	The New “Post-Expiry” Opportunities	27
3.7	Shift toward Automation in iPSC Production	28
3.8	Current Utilization of Genome-Editing Tools in iPSCs	28
3.9	Current Utilization of Organoids & 3D Tissues in iPSC-Derived Disease Models	29
3.10	Significant increase in the number of Market Participants	30
3.10.1	Types of iPSC-Related Companies in 2026	30
3.10.1.1	The iPSC Therapeutics Developers (Clinical & Preclinical) Companies	30
3.10.1.2	iPSC Product & Research Tool Suppliers.....	31
3.10.1.3	Contract Development and Manufacturing Organizations (CDMOs)	31
3.10.1.4	Longevity and Rejuvenation Companies (Partial Reprogramming)	31
4.	IPSC MANUFACTURING	32
4.1	Tissue Acquisition and Donor Screening.....	32
4.2	Somatic Cell Isolation and Priming.....	33
4.2.1	Isolation of Dermal Fibroblasts	33
4.3	Reprogramming of Somatic Cells into iPSCs	33
4.4	Expansion and Selection of iPSC Colonies.....	34
4.4.1	Selection of iPSC Colonies after Reprogramming.....	34
4.5	Directed Differentiation of iPSCs into Specific Cell Types	35
4.6	Development of Organoids from iPSCs.....	35
4.6.1	Key Steps in iPSC-Derived Organoid Development.....	36
5.	RESEARCH PUBLICATIONS ON INDUCED PLURIPOTENT STEM CELLS	37
5.1	Rapid Growth of iPSC Publications in PubMed.gov	38
5.2	Categories of iPSC Research Themes.....	39
5.2.1	PubMed Published iPSC Papers on Pathophysiological Studies.....	40
5.2.2	PubMed Published iPSC Papers on Reprogramming Studies	41
5.2.3	PubMed Published Papers on iPSC Differentiation Studies.....	42
5.2.4	PubMed Published Papers on iPSC-based Drug Discovery	43
5.2.5	PubMed Published Papers on iPSC-based Cell Therapy.....	44
5.2.6	Future Trends in iPSC Research	45
5.2.6.1	Anticipated advancements in Therapeutic Applications	45
5.2.6.2	Enhanced Disease Modeling and Drug discovery.....	46
5.2.6.3	Technological Innovations and Automation.....	46
5.2.6.4	Future Research Directions and Challenges.....	47

6.	IPSC PATENT LANDSCAPE	48
6.1	iPSC Patent Applications by Jurisdiction	49
6.2	iPSC Patent Applicants	50
6.3	Inventors of iPSC Patent Applications	54
6.4	Major iPSC Patent Owners	57
6.5	Current Legal Status of iPSC Patents	60
6.5.1	Granted iPSC Patents	61
6.5.2	Key Technology Areas Protected	61
6.5.3	Geographical Trends in iPSC Granted Patents	62
6.5.4	Recently Granted iPSC Patents (2024-2026)	62
6.5.4.1	Recent Patent of RxCell, Inc.	62
6.5.4.2	Recent Patent of Pluristyx	63
6.5.4.3	Recent Patent of Applied StemCell, Inc.	63
6.5.4.4	Recent Patent of iPS Academia Japan/Kyoto University	63
6.5.4.5	Recent Patent of Allele Biotechnology	63
6.6	Recent iPSC Patent Licensing Activity	63
6.6.1	Licensing Fees for iPSC Patents	64
6.7	The Future Direction of Growth in iPSC Patent Activity	64
6.7.1	The “Patent Cliff” and Focus Shift	64
7.	CLINICAL TRIAL LANDSCAPE: INDUCED PLURIPOTENT STEM CELLS	65
7.1	Late-Stage iPSC Clinical Trials & Progress	65
7.2	Current Recruitment Status	66
7.3	iPSC Clinical Trials by Study Designs	66
7.4	Therapeutic & Non-Therapeutic iPSC Clinical Trials	67
7.4.1	The iPSC Non-Therapeutic Clinical Studies by Use	68
7.4.2	Diseases Targeted by Therapeutic Studies	69
7.4.3	The iPSC Clinical Trials Addressing Ocular Diseases	71
7.4.4	Trials IPSC-Based Clinical Trials Addressing CNS Disorders	71
7.4.5	IPSC-Derived Cardiomyocytes and Muscle Products in Clinical Trials	72
7.4.6	IPSC-Based in Immune and Blood Products Clinical Trials	73
7.4.7	Stromal Products in Clinical Trials	73
7.5	iPSC-based Clinical Trials by Phase of Study	74
7.6	iPSC Clinical Trials by Funder Type	75
7.7	Geographic Distribution of iPSC Clinical Trials	76
7.8	Predicted Future Directions of iPSC-Based Clinical Trials	78
8.	M&A, COLLABORATIONS AND FUNDING ACTIVITIES IN IPSC SECTOR	80
8.1	Mergers and Acquisitions (M&A) in iPSC Sector	80
8.1.1	Axol Biosciences’ Acquisition of Newcells Biotech	80
8.1.2	Acquisition of Phenocell by Axol Biosciences	81
8.1.3	Acquisition of Clade Therapeutics by Century Therapeutics	81
8.2	Partnership/Collaboration & Licensing Deals in iPSC Sector	82
8.2.1	Cartherics & Catalent	83
8.2.2	Applied StemCell, Inc. & Cellipont Bioservices	83
8.2.3	GelMEDIX & Catalent	83
8.2.4	ISCT & JSRM	83
8.2.5	SmartCella Holding & Catalent	84
8.2.6	Mytos & Pluristyx	84
8.2.7	Cell X Technologies & BioLamina	84
8.2.8	Pluristyx & Solesis	84
8.2.9	Pluristyx & BioLamia	85
8.2.10	Celaid Therapeutics & AGC	85
8.2.11	Cellino & Karis Bio	85
8.2.12	Ginkgo Bioworks & Universal Cells	85
8.2.13	BrightPath Bio & Cellistic	86

8.2.14	Alloy Therapeutics & Takeda	86
8.2.15	Factor Bioscience & Eterna Therapeutics	86
8.2.16	Aspen Neuroscience & Cell X Technologies	86
8.2.17	Shinobi Therapeutics & Panasonic	87
8.2.18	SCG Cell Therapy and A*STAR	87
8.2.19	Charles River Laboratories & Pluristyx	87
8.2.20	Pluristyx & National Resilience, Inc	87
8.2.21	University of Texas & GeneCure	88
8.2.22	BlueRock Therapeutics & Bit.bio	88
8.2.23	Applied Stem Cell, Inc. & CIRM	88
8.3	Venture Capital Funding in iPSC Sector	89
8.3.1	Trailhead Biosystems, Inc.	90
8.3.2	Morphocell Technologies, Inc.	90
8.3.3	Aspen Neuroscience, Inc.	90
8.3.4	Celaid Therapeutics, Inc.	91
8.3.5	GC Therapeutics, Inc.	91
8.3.6	iRegene Therapeutics	91
8.3.7	Gameto	92
8.3.8	Pluristyx.....	92
8.3.9	Asgard Therapeutics	92
8.3.10	Kenai Therapeutics	93
8.3.11	Pluristyx.....	93
8.3.12	Fujifilm Cellular Dynamics.....	93
8.3.13	Mogrify, Ltd.	93
8.3.14	Heartseed, Inc.	94
8.3.15	Elevate Bio	94
9.	GENERATION OF INDUCED PLURIPOTENT STEM CELLS (IPSCS)	95
9.1	Reprogramming Factors (OSKM Cocktail/Yamanaka Factors).....	95
9.1.1	Roles of OSKM Factors in the Induction of iPSCs.....	96
9.1.2	Companies offering Reprogramming Services	97
9.2	Direct Reprogramming.....	97
9.2.1	Companies offering Direct Reprogramming Services.....	98
9.3	Delivery of Reprogramming Factors.....	99
9.3.1	Currently Favored Reprogramming Factors	100
9.3.1.1	Sendai Virus (SeV) Reprogramming (Gold Standard)	100
9.3.1.2	mRNA-Based Reprogramming (High Safety).....	100
9.3.1.3	Episomal Plasmid Vectors (Simplicity)	100
9.3.1.4	Comparative Efficacies of Reprogramming Methods	100
9.4	Genome Editing Technologies in iPSC Generation	101
9.4.1	Companies offering CRISPR/Cas9 Services for iPSC Generation	101
9.5	Development of iPSC-Derived Organoids	102
9.5.1	Companies Developing iPSC-Derived Organoids	102
9.6	Development of iPSC-Derived Cardiac Tissue Sheets	103
9.7	Development of iPSC-Derived RPE Sheets	104
10.	HUMAN IPSC BANKING	105
10.1	EBiSC	105
10.1.1	IPSCs Available with EBiSC	106
10.2	RIKEN BRC	107
10.2.1	The iPSC Lines available with RIKEN BRC.....	107
10.3	CiRA.....	107
10.4	WiCell.....	108
10.5	HipSci.....	109
10.6	hPSCreg	109
10.7	inStem.....	109

10.8	Coriell Institute for Medical Research	110
10.8.1	Cell Lines offered by Coriell	110
10.9	Cost Difference for iPSC Lines between Non-Profit Banks and Commercial Providers	110
10.10	Cell Sources & Reprogramming Methods in iPSC Banks.....	111
10.11	Ownership and Funding for iPSC Banks.....	111
11.	BIOMEDICAL APPLICATIONS OF IPSCS.....	112
11.1	Applications of iPSCs in Basic Research	113
11.1.1	Consumption of iPSC lines in Research	114
11.1.2	Providers of iPSC Research Products for Researchers	114
11.1.3	Product Categories used in iPSC Research	115
11.1.3.1	The iPSC Reprogramming Kits	115
11.1.3.2	Culture Media & Reagents used in Research	116
11.1.3.3	Differentiated iPS Cells used in Research	116
11.1.3.4	3D Organoids from iPSCs for Research	117
11.1.3.5	Specialized Services in iPSC Manufacturing	118
11.1.3.6	Procurement of iPSC-based Research Products by Researchers	119
11.1.3.6.1	Procurement from Commercial Suppliers	119
11.1.3.6.2	Procurement from Public and Private Repositories	119
11.1.3.6.3	Direct Generation/Custom Services.....	120
11.2	Applications of iPSCs in Drug Discovery.....	120
11.2.1	Applications of iPSCs in Patient-Specific Disease Modeling	120
11.2.1.1	Companies offering iPSC-Derived Cardiomyocytes for Drug Discovery	121
11.2.1.1.1	Drugs Tested for Cardiovascular Diseases using iPSCs.....	122
11.2.1.2	Companies offering iPSC-derived Neuronal Cells for Drug Discovery	123
11.2.1.2.1	Drugs Tested for Neurological Diseases using iPSCs.....	124
11.2.1.3	Companies offering iPSC-Derived RPEs	124
11.2.1.3.1	Drugs Tested for Ocular Diseases using iPSC Lines	125
11.2.1.4	Companies developing iPSCs to Discover Drugs for Metabolic Diseases	126
11.2.1.4.1	Drugs Tested in iPSCs for Metabolic Diseases	127
11.2.1.5	Companies Developing iPSCs to Discover Drugs for Blood Disorders	127
11.2.1.5.1	Drugs Tested for Blood Disorders using iPSCs	128
11.2.1.6	The iPSCs in High-Throughput Screening (HTS)	129
11.2.1.7	The iPSCs in Drug Toxicity and Safety Assessment	129
11.2.1.7.1	Companies offering Toxicity Testing Services using iPSC-Derived Cells	130
11.2.1.7.2	Drugs Tested for their Toxicity using iPSC Lines	131
11.2.1.7.3	Relative Use of iPSC-Derived Cell Types used in Toxicity Testing Studies	132
11.2.1.8	The iPSCs in Personalized Medicine and Genomic Studies	133
11.2.3	Applications of iPSC-Derived Cells in Cell Therapies (Regenerative Medicine)	133
11.2.3.1	Companies developing iPSC-based Cell Therapies	134
11.2.3.2	The Landscape of iPSC-Based Cell Therapy Clinical Trials.....	135
11.2.3.2.1	Key Therapeutic Targets in iPSC-Based Cell Therapy Clinical Trials	136
11.2.3.2.2	iPSC-Based Cell Therapy Clinical Trials.....	136
11.2.4	Other Novel Applications of iPSCs	137
11.2.4.1	Bioinks for Tissue Engineering.....	138
11.2.4.1.1	Companies developing iPSC-Based Bioinks	138
11.2.4.2	The iPSCs in the Conservation of Endangered Species	138
11.2.4.2.1	Key Applications of iPSCs Conservation	138
11.2.4.2.2	Major Conservation Programs using iPSCs	139
11.2.4.2.3	Development of iPSCs from Domestic & Wild Animals	139
11.2.4.3	Cultured Meat Production using iPSCs.....	140
11.2.4.3.1	Companies Developing Cultured Meat using iPSCs	141
11.3	Cost of iPSC-Based Products & Services	141
12.	MARKET ANALYSIS.....	143
12.1	Global Market for Induced Pluripotent Stem Cells (iPSCs) by Geography	144

12.2	Global Market for iPSCs by Market Segments	146
12.3	Global Market for iPSC-based Reprogramming Technologies	147
12.4	Global Market for iPSC-Derived Cell Types	149
12.5	Global Market for Manual & Automated iPSC Production Services	150
12.5.1	Market Share for Key Modules in iPSC Production	150
12.5.2	Market Shares of Products Utilized in iPSC Manufacturing	151
12.5.3	Percent Market Share of iPSC-Derived Cells by End-Use, 2025	152
12.6	Key iPSC Market Drivers	153
12.7	Key iPSC Market Restraints	154
12.8	Predicted Shifts in iPSC market.....	154
12.8.1	Shift from Research to Clinical Applications	155
12.8.2	Technological Shifts in Production and Quality	155
12.8.3	Application & Therapeutic Shifts	155
12.8.4	Regional & Strategic Shifts	155
13.	COMPANY PROFILES	156
13.1	28bio	157
13.1.1	The Nexon™ platform	157
13.1.2	CNS-3D Technology	158
13.1.3	CNS-3D Organoid Services	158
13.1.4	PNS-3D Organoids	158
13.1.5	PNS-3D Organoid Services	158
13.2	AcceGen	159
13.2.1	Treatments for Neurodegenerative Diseases with iPSCs	159
13.2.2	AcceGen's Pipeline	159
13.3	Accellta, Ltd.	160
13.3.1	Accellta's Foodtech	160
13.3.2	Accellta's Biotech Services	160
13.3.3	Accellta's Core Technology	160
13.4	Alder Therapeutics.....	161
13.5	Aldevron.....	162
13.5.1	Key Products and Services for iPSC	162
13.6	Allele Biotechnology	163
13.6.1	mRNA Reprogramming.....	163
13.6.2	mRNA Differentiation	163
13.7	Altos Labs	164
13.8	Applied StemCell, Inc. (ASC).....	164
13.8.1	Genome Editing Platforms	165
13.8.2	The iPSC Drug Discovery Platform.....	165
13.8.3	The iPSC Gene Editing Services.....	165
13.8.4	The iPSC Differentiation Services.....	165
13.8.5	The iPSC Generation Services	166
13.8.6	Product Offerings	166
13.9	Arktus Therapeutics, Co., Ltd.	167
13.9.1	Technologies	167
13.10	Aspen Neuroscience	168
13.10.1	Autologous Manufacturing Process.....	168
13.10.2	Aspen's Clinical Pipeline.....	168
13.11	ATCC.....	169
13.11.1	Product Offerings.....	169
13.12	Axxam S.p.A.....	170
13.12.1	The iPSC Platform Capabilities	170
13.13	Axol Bioscience	171
13.13.1	Products.....	171
13.13.2	Services	172
13.13.3	iPSC-derived Models	172

13.14	BD Biosciences	173
13.14.1	Key Contributions and Tools	173
13.15	Bit.bio.....	174
13.15.1	Products & Services	174
13.15.1.1	Human iPSC-derived glial cells	174
13.16	BlueRock Therapeutics	175
13.16.1	BlueRock's Cell Therapy Programs.....	175
13.16.1.1	Neurology Program	175
13.16.1.2	Ophthalmology Program	176
13.17	BPS Bioscience	177
13.17.1	Product Offerings.....	177
13.18	BrainXell	178
13.18.1	Product Offerings.....	178
13.18.2	Services Offered	178
13.19	BrainZell	179
13.19.1	Technology	179
13.19.2	Selection of Source Cells.....	179
13.20	BrightPath Biotherapeutics Co., Ltd.	180
13.21	Cartherics Pty Ltd.....	181
13.21.1	CTH-401	181
13.21.2	CTH-004	181
13.22	Catalent, Inc.	182
13.22.1	Services	182
13.23	Celogics.....	183
13.23.1	Custom Cardiomyocytes.....	183
13.24	Celregen Therapeutics	184
13.24.1	Core Platform Technologies	184
13.24.2	Key iPSC Product Candidates.....	185
13.25	Collectis	185
13.25.1	TALEN® Technology	185
13.25.2	PulseAgile Technology	186
13.26	CellGenix GmbH.....	187
13.26.1	Key Contributions	187
13.27	Cellistic	188
13.27.1	CDMO Services	188
13.27.2	Allo Chassis™ Platform	188
13.27.3	STAR-CRISPR™ Technology	189
13.27.4	Pulse Cell Line Development Platform	189
13.27.5	Cellistic's Echo Manufacturing Platform	189
13.27.6	GMP Manufacturing.....	189
13.27.7	ECHO™-NK Platform	189
13.27.8	Echo™-Cardio platform	190
13.27.9	Echo™-Endothelial Platform	190
13.27.10	Echo™-T Platform	190
13.28	CellSystems GmbH	191
13.28.1	Core Competencies in iPSC Technology	191
13.29	Cellusion, Inc.	192
13.29.1	CECSI Cells.....	192
13.30	Celregen Therapeutics	193
13.30.1	Products in Development.....	193
13.30.1.1	Islet Cells	193
13.30.1.2	The iCEnCs	194
13.31	Century Therapeutics	195
13.31.1	Century's Approach	195
13.31.2	Century's Precision Gene Editing Technology	195
13.31.2.1	Allo-Evasion™ Technology	195

13.31.3	Century's Pipeline Overview	196
13.32	Citius Pharmaceuticals, Inc.	197
13.32.1	Induced Mesenchymal Stem Cells (i-MSCs)	197
13.33	clock.bio.....	198
13.33.1	The clock.bio's Platform.....	198
13.33.1.1	The geneAge Atlas of Aging and Rejuvenation Genes.....	198
13.33.1.2	The imAge	198
13.33.1.3	The clinAge Platform	199
13.34	Creative Medical Technology Holdings, Inc.	199
13.34.1	The iPSCelz® Program	199
13.35	CUORIPS, Inc.....	200
13.35.1	Conditional Approval for ReHeart in Japan	200
13.35.1.1	Treatment Modality for ReHeart.....	200
13.36	Curi Bio, Inc.	201
13.36.1	Curi Bio's Biosystem Platforms	201
13.36.2	3D Engineered Models	202
13.36.3	The Curi Engine™: Custom Services.....	202
13.37	Cynata Therapeutics	203
13.37.1	Cymerus™ Technology	203
13.37.2	Clinical Development	204
13.38	CytoMed Therapeutics Limited.....	205
13.38.1	iPSC-γδ NKT Cell Technology	205
13.39	Defined Bioscience, Inc.	206
13.39.1	Products for Disease Modeling.....	206
13.40	Editas Medicine	207
13.40.1	Edita's iPSC Platform	207
13.41	EditCo Bio, Inc.....	208
13.41.1	Services	208
13.41.2	CRISPR Reagents & Kits	208
13.42	ErneXa Therapeutics.....	209
13.43	Esco Lifesciences.....	210
13.43.1	Key Contributions	210
13.44	Evotec.....	211
13.44.1	Services	211
13.45	Eyestem Research Pvt. Ltd.....	212
13.45.1	Eyecyte-RPE™	212
13.45.2	Eyecyte-PRPTM	212
13.45.3	AAV mediated gene augmentation.....	213
13.46	Factor Biosynthesis, Inc.	213
13.46.1	The mRNA Reprogramming Technology Platforms	213
13.46.2	UltraSlice™ Gene Editing Technology Platforms	214
13.47	Fate Therapeutics, Inc.....	214
13.47.1	Fate Therapeutics' iPSCs Platform	215
13.47.2	Fate Therapeutics' Pipeline Overview	215
13.48	FUJIFILM Cellular Dynamics.....	216
13.48.1	Products.....	216
13.48.2	Custom Services.....	216
13.48.3	The iPSC CDMO Services.....	217
13.49	Gameto, Inc.	217
13.49.1	Gameto's Science.....	217
13.49.1.1	Fertilo.....	218
13.49.1.2	Ameno	218
13.49.1.3	Deovo	218
13.50	GC Therapeutics	219
13.50.1	TFome™ Platform	219
13.51	GenScript.....	220

13.51.1	iPSC-Related Services	220
13.51.2	iPSC-Related Products.....	220
13.52	GOLIVER THERAPEUTICS.....	221
13.52.1	GOLIVER Solution.....	221
13.53	Greenstone Biosciences	222
13.53.1	Products.....	222
13.53.2	Services	223
13.54	Healios K.K.....	224
13.55	HeartBeat.bio AG	225
13.55.1	Cardioids (Cardiac Organoids)	225
13.55.1.1	Cardioid Drug Discovery Platform	225
13.55.2	Disease Models	226
13.55.3	Assays	226
13.55.4	Drug Discovery Strategy.....	226
13.56	Heartseed, Inc.	227
13.56.1	Remuscularization Technology	227
13.56.2	Cardiomyocyte Spheroid	227
13.57	Hebecell Corporation.....	228
13.57.1	ProtoNK™.....	228
13.57.2	Contract Manufacturing Services	228
13.58	HELP Therapeutics	230
13.59	Herophilus	231
13.59.1	Herophilus' Approach	231
13.60	Hesperos, Inc.	232
13.60.1	Human-on-a-Chip®.....	232
13.61	Horizon Discovery	233
13.62	HUB Organoids BV	234
13.62.1	Products.....	234
13.63	iCamuno Biotherapeutics	235
13.63.1	Transient Naïve Treatment (TNT)	235
13.64	iHeart Japan Corporation	236
13.64.1	Contract Services	236
13.65	IN8Bio.....	237
13.65.1	INB-500.....	237
13.66	InSphero	238
13.66.1	Products & Services	238
13.67	iPeace, Inc.....	239
13.67.1	Products.....	239
13.67.2	Manufacturing Service	239
13.68	iPS Academia Japan, Inc.	240
13.68.1	Key Aspects of iPS Academia Japan, Inc.	240
13.69	IPS HEART.....	241
13.69.1	Proprietary Platform.....	241
13.69.1.1	ISX9-CPC	241
13.69.1.2	GIVI-MPC	241
13.70	iPSirius	242
13.70.1	iPVAC Technology.....	242
13.70.2	iPSirius' Pipeline	243
13.71	iRegene Therapeutics	244
13.71.1	iReDita Platform.....	244
13.72	iXCells Biotechnologies.....	245
13.72.1	iXCells' Core Services	245
13.72.2	Products.....	246
13.72.2.1	Organoids	246
13.73	iXgene, Inc.....	247
13.73.1	Technology	247

13.74	Jacobio Pharmaceuticals	248
13.74.1	Jacobio's iPSC Collaboration with Hebecell	248
13.75	Kangstem Biotech	249
13.76	Kenai Therapeutics	250
13.76.1	Kenai's iPSC Platform	250
13.76.2	Kenai's Pipeline	250
13.77	Khloris Biosciences, Inc.	251
13.78	Kiji Therapeutics	252
13.79	Lambda Biologics GmbH.....	253
13.79.1	Organoid Services	253
13.80	Laverock Therapeutics	254
13.80.1	iPSC-derived Cell Therapies	254
13.81	Lineage Cell Therapeutics.....	255
13.82	Lonza.....	256
13.82.1	Key Contributions	256
13.83	Megakaryon Corporation.....	257
13.83.1	Technology	257
13.83.2	Megakaryons R&D Pipeline.....	258
13.84	Miltenyi Biotec, Inc.	259
13.84.1	Tools for Manual iPSC Workflows	259
13.84.2	Automated and Closed iPSC Manufacturing	260
13.85	Morphocell Technologies, Inc.....	260
13.85.1	ReLiver.....	260
13.86	Myoridge Co. Ltd.	261
13.86.1	Products & Services	261
13.87	Ncardia	262
13.87.1	Products.....	262
13.87.2	Services	262
13.88	NeuCyte, Inc.....	263
13.88.1	Technology	263
13.88.2	NeuCyte's Services	263
13.89	Neukio Biotherapeutics	264
13.90	NEXEL.....	264
13.90.1	Organoids	264
13.90.2	iPSC Derived Cells	265
13.90.3	Instruments	265
13.90.4	NeXST (Next Xight Screening Test)	265
13.90.5	Disease Modeling	265
13.90.6	Cell Customization.....	265
13.90.7	Services	266
13.91	Okomera.....	266
13.91.1	Ocentra	266
13.92	Organovo Holdings, Inc.	267
13.92.1	Product Pipeline.....	267
13.93	Orizuru Therapeutics.....	268
13.94	Oxford StemTech	269
13.94.1	Services Offered	269
13.95	Parallel Bio	270
13.96	Pixl Bio, Ltd.....	270
13.96.1	Platform.....	270
13.96.2	Products.....	271
13.96.2.1	The pixStellate iPSC-derived Stellate Cells	271
13.96.2.2	pixHep/pixStellate Co-Culture Models	271
13.96.2.3	MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Models.....	271
13.96.2.4	The pixHep A1ATD (Alpha-1 Antitrypsin Deficiency) Models	271
13.96.2.5	The pixHep PFIC2 (Progressive Familial Intrahepatic Cholestasis Type 2) Model.....	272

13.96.2.6	The pixHep UCD (Urea Cycle Disorder) Models (ASS1, and OTC)	272
13.97	Pluristyx, Inc.	273
13.97.1	FailSafe Cell System	273
13.97.2	iACT Stealth Cells™	273
13.97.3	Products	274
13.97.3.1	PluriBank™	274
13.97.3.2	PluriForm™ Kit	274
13.97.3.3	PluriFreeze™ Cryopreservation System	274
13.97.3.4	PluriKit™	274
13.97.4	iPSC Generation	275
13.97.5	Differentiated Cells	275
13.98	Porosome Therapeutics, Inc.	276
13.98.1	iPSC Derived Beta Cell T1D Therapy	276
13.99	Quell Therapeutics Ltd	277
13.99.1	Collaboration for iPSCs	277
13.100	Racthera Co., Ltd.	278
13.100.1	Amchepry®	278
13.100.2	Racthera's Retinal Sheet (DSP-3077)	279
13.100.3	Racthera's Retinal pigment epithelial cells (HLCR011)	279
13.100.4	Racthera's Neural progenitor cells (SMP-0115)	280
13.101	Rege Nephro, Co., Ltd.	281
13.101.1	RN-032	281
13.102	Repairon GmbH	282
13.102.1	Technology	282
13.103	ReproCELL	283
13.103.1	Services	283
13.103.2	Product Offerings	284
13.103.3	ReproCELL's Clinical Pipelines	285
13.104	Res Nova Biologics	286
13.105	Ricoh Biosciences, Inc.	287
13.105.1	Products	287
13.105.2	Ricoh's iPSC-related Services	288
13.105.3	Ricoh's Therapeutics Development Pipeline	288
13.106	Sampled	289
13.106.1	Services	289
13.107	Sana Biotechnology	290
13.108	Sarcio, Inc.	291
13.108.1	SEV-101	291
13.108.2	SEVA-101	291
13.109	SCG Cell Therapy, Pte. Ltd.	292
13.110	SereNeuro Therapeutics	292
13.111	Shinobi Therapeutics	293
13.112	STEMCELL Technologies	294
13.112.1	Services	294
13.113	StemCardia	295
13.113.1	Core Product & Technology	295
13.114	StemSight	296
13.114.1	StemSight's Technology	296
13.115	Stemson Therapeutics	297
13.115.1	KeyProduct & Service Portfolio	297
13.116	Stimuliver	298
13.117	Sumitomo Pharma	299
13.118	Synthego	300
13.118.1	Core Capabilities	300
13.119	Telescope Therapeutics	301
13.119.1	Core Cellular & Technology Platforms	301

13.120	Tempo Bioscience	302
13.120.1	Products	302
13.121	Tenaya Therapeutics	303
13.121.1	Drug Development Capability	303
13.121.2	Disease Models	303
13.122	TGD Life Company Limited	304
13.122.1	R&D Services	304
13.123	Thermo Fisher Scientific Inc.	305
13.123.1	Key Contributions	305
13.124	Tolerance Bio	306
13.125	Trailhead Biosystems®	306
13.125.1	HD-DoE (high-dimensional design-of-experiments) technology	307
13.125.2	Trailhead's Hematopoietic Progenitor Cells	307
13.125.3	hiPSC-derived Dopaminergic Neurons	307
13.125.4	hiPSC-derived Pancreatic Beta Cells	307
13.126	TreeFrog Therapeutics	308
13.126.1	C-Stem™	308
13.127	Vanqua Bio	309
13.127.1	Pipeline	309
13.128	Vascugen, Inc.	310
13.128.1	Core Technology & Approach	310
13.129	VCCT Inc.	311
13.129.1	VCCT's Product Candidates	311
13.130	Vertex Pharmaceuticals	313
13.130.1	Key iPSC-Based Products & Programs	313
13.131	Vivodyne	314
13.131.1	Lab-Grown Organs	314
13.132	Yashraj Biotechnology, Ltd.	315
13.132.1	Products	315
13.132.1.1	Induced Pluripotent Stem Cell (iPSC) Lines	315
13.132.1.2	iPSC-Derived Cardiomyocytes (YBLiCardio)	316
13.132.1.3	iPSC-Derived Hepatocytes Like Cells (YBLiHepato)	316

INDEX OF FIGURES

FIGURE 5.1: Rapid Growth of iPSC Publications in PubMed.gov	39
FIGURE 5.2: PubMed Published iPSC Papers on Pathophysiological Studies	40
FIGURE 5.3: PubMed Published iPSC Papers on Reprogramming Studies	41
FIGURE 5.4: PubMed Published Papers on iPSC Differentiation Studies	42
FIGURE 5.5: PubMed Published Papers on iPSC-based Drug Discovery	43
FIGURE 5.6: PubMed Published Papers on iPSC-based Cell Therapy	44
FIGURE 6.1: Number of iPSC Patents filed per Year, 2000-April 3, 2026	49
FIGURE 7.1: iPSC Clinical Trials by Study Designs	67
FIGURE 7.2: Therapeutic & Non-Therapeutic iPSC Clinical Trials	68
FIGURE 7.3: Non-Therapeutic iPSC Clinical Trials by Use	69
FIGURE 7.4: Percent Share of Diseases Targeted by Therapeutic Studies	70
FIGURE 7.5: iPSC Clinical Trials by Funder Type	76
FIGURE 7.6: Geographic Distribution of iPSC Clinical Trials	78
FIGURE 9.1: Roles of OSKM Factors in the Induction of iPSCs	96
FIGURE 9.2: Delivery Methods for Reprogramming Factors	99
FIGURE 11.1: Biomedical Applications of iPSCs	112

FIGURE 11.2: Potential of iPSCs in Toxicity Testing and Drug Screening	130
FIGURE 11.3: Relative Use of iPSC-Derived Cell Types used in Toxicity Testing Studies	132
FIGURE 12.1: Global Market for iPSCs by Geography, 2025-2034.....	145
FIGURE 12.2: Global Market for iPSCs by Market Segments.....	147
FIGURE 12.3: Global Market for iPSC-Related Reprogramming Technologies, 2026-2034	148
FIGURE 12.4: Global Market for iPSC-Derived Cell Types, 2025.....	149
FIGURE 12.5: Global Market for Manual & Automated iPSC Production Services, 2025	150
FIGURE 12.6: Market Share for Key Modules in iPSC Production, 2025	151
FIGURE 12.7: Market Shares of Products Utilized in iPSC Manufacturing, 2025.....	152
FIGURE 12.8: Percent Market Share of iPSC-Derived Cells by End-Use, 2025	153

INDEX OF TABLES

TABLE 3.1: Examples of iPSC-based Autologous & Allogeneic Products in Phase II	24
TABLE 3.2: Disease Areas Focused by iPSC-based Clinical Trials.....	25
TABLE 3.3: Companies Providing AI-Powered Automation Services	26
TABLE 3.4: Key Platforms used in Automatic iPSC Production	28
TABLE 4.1: Donor Selection and Screening Process.....	32
TABLE 4.2: Common Sources of Somatic Cells for Reprogramming into iPSCs.....	33
TABLE 4.3: Key Reprogramming Vectors used in iPSC Generation	34
TABLE 4.4: Methods of selecting iPSC Colonies after Reprogramming	34
TABLE 4.5: Examples of Differentiated Cell Types from iPSCs	35
TABLE 4.6: Examples of iPSC-Derived Organoids	36
TABLE 5.1: Landmark Publications in iPSC Research.....	37
TABLE 5.2: Rapid Growth of iPSC Publications in PubMed.gov.....	38
TABLE 5.3: Anticipated advancements in iPSC-based therapeutic applications	45
TABLE 5.4: Enhanced Disease Modeling and Drug Discovery	46
TABLE 5.5: Technological Innovations and Automation.....	46
TABLE 6.1: Number of Patents filed per year, 1993-April 3, 2026	48
TABLE 6.2: iPSC Patent Applications by Jurisdiction as of April 3, 2026	50
TABLE 6.3: Top 100 iPSC Patent Applicants as of April 3, 2026	52
TABLE 6.3: (CONTINUED)	53
TABLE 6.3: (CONTINUED)	54
TABLE 6.4: Top 100 Inventors of iPSC Patent Applications	55
TABLE 6.4: (Continued)	56
TABLE 6.4: (CONTINUED)	57
TABLE 6.5: Top 100 Owners of iPSC Patent Applications	58
TABLE 6.5: (CONTINUED)	59
TABLE 6.5: (CONTINUED)	60
TABLE 6.6: Legal Status of iPSC Patent Applications as of April 4, 2026	61
TABLE 6.7: Recently Granted iPSC Patents (2024-2026)	62
TABLE 6.8: Licensing Fees for iPSC Patents.....	64
TABLE 7.1: Late-Stage iPSC Clinical Trials & Progress	65
TABLE 7.2: Recruitment Status of iPSC Clinical Trials, 2023-2026.....	66
TABLE 7.3: Select Clinical Trials in Ocular Diseases.....	71
TABLE 7.4: Select Clinical Trials Focusing on CNS Disorders	72
TABLE 7.5: Select Clinical Trials Focusing on iPSC-Based Cardiomyocytes and Muscle Products.....	72
TABLE 7.6: Select Clinical Trials focusing on iPSC-Based in Immune and Blood Products	73
TABLE 7.7: Select Stromal Products in Clinical Trials.....	74

TABLE 7.8: iPSC-based Clinical Trials by Phase of Study.....	75
TABLE 7.9: Geographic Distribution of iPSC Clinical Trials	77
TABLE 7.10: Key Future Directions of iPS-Based Trials	79
TABLE 8.1: M&A Deals signed in iPSC Sector, 2023-2026	80
TABLE 8.2: Collaboration/Partnership & Licensing Deals in iPSC Sector, 2023-2026	82
TABLE 8.3: Venture Capital Funding Raised by iPSC Companies, 2021-April 2026.....	89
TABLE 9.1: Core Reprogramming Factors (OSKM).....	96
TABLE 9.2: Top Companies offering iPSC Reprogramming Services	97
TABLE 9.3: Key Combination of Factors for Direct Reprogramming.....	98
TABLE 9.4: Companies Involved in Direct Reprogramming Services	98
TABLE 9.5: Efficacy of iPSC Reprogramming Methods	101
TABLE 9.6: Companies offering CRISPR/Cas9 Services for iPSC Generation	102
TABLE 9.7: Key Companies developing iPSC-Derived Organoids	103
TABLE 9.8: Key Companies developing iPSC-Derived Cardiac Tissue Sheets	103
TABLE 9.9: Companies developing iPSC-Derived RPE Sheets	104
TABLE 10.1: Key Human iPSC Banks.....	105
TABLE 10.2: iPSC Lines available with EBiSC.....	106
TABLE 10.3: Price List for CiRA's Clinical Grade iPSCs	108
TABLE 10.4: Cell Types Banked by WiCell	108
TABLE 10.5: iPS Cell Lines in Coriell's Collection.....	110
TABLE 10.6: Cell Sources & Reprogramming Methods in iPSC Banks	111
TABLE 10.7: Ownership & Funding for iPSC Banks	111
TABLE 11.1: Top Providers of iPSC Research Products for Researchers	114
TABLE 11.2: Commonly used iPSC Reprogramming Kits	115
TABLE 11.3: Commonly used Culture Media and Reagents in Research	116
TABLE 11.4: Key Companies offering iPSC-Derived Cell Types for Research	117
TABLE 11.5: Companies providing iPSC-Derived 3D Organoids for Research.....	117
TABLE 11.6: Companies offering iPSCs-related Specialized Services.....	118
TABLE 11.6: (CONTINUED)	119
TABLE 11.7: Key Companies involved in Patient-Specific Disease Modeling	121
TABLE 11.8: Companies offering iPSC-Derived Cardiomyocytes for Drug Discovery.....	121
TABLE 11.9: Cardiovascular Drugs Tested in iPSC Models	122
TABLE 11.10: Companies offering iPSC-derived Neuronal Cells for Drug Discovery	123
TABLE 11.11: Drugs Tested for Neurological Diseases using iPSCs	124
TABLE 11.12: Companies offering iPSC-Derived RPEs	125
TABLE 11.13: Drugs Tested for Ocular Diseases using iPSC Lines.....	125
TABLE 11.14: Companies developing iPSCs to Discover Drugs for Metabolic Diseases	126
TABLE 11.15: Drugs Tested in iPSCs for Metabolic Diseases.....	127
TABLE 11.16: Companies developing iPSCs to Discover Drugs for Blood Disorders	128
TABLE 11.17: Drugs Tested for Blood Disorders using iPSCs	128
TABLE 11.18: Key Companies offering HTS Services using iPSCs	129
TABLE 11.19: Companies offering Toxicity Testing Services using iPSCs.....	131
TABLE 11.20: Drugs Tested for their Toxicity using iPSC Lines	131
TABLE 11.21: Companies using iPSCs in Personalized Medicine and Genomic Studies.....	133
TABLE 11.22: Key Applications of iPSC-Derived Cells in Cell Therapy.....	134
TABLE 11.23: Key Players & Focus Areas in iPSC-Based Cell Therapy.....	135
TABLE 11.24: Key Therapeutic Targets in iPSC-Based Cell Therapy Clinical Trials.....	136
TABLE 11.25: Select iPSC-Based Cell Therapy Clinical Trials	137
TABLE 11.26: Major Conservation Initiatives & Species	139
TABLE 11.27: Companies developing Cultured Meat using iPSC-Derived Cells.....	141

TABLE 12.1: Global Market for iPSCs by Geography, 2025-2034	145
TABLE 12.2: Global Market for iPSCs by Market Segments	146
TABLE 12.3: Global Market for iPSC-Related Reprogramming Technologies, 2026-2034	148
TABLE 13.1: AcceGen's Pipeline Product Candidates.....	159
TABLE 13.2: Aspen's Clinical Pipeline	168
TABLE 13.3: BlueRock's Pipeline Focusing on New Therapies	176
TABLE 13.4: BrightPath's Product Pipeline	180
TABLE 13.5: Cartheric's R&D Pipeline of Allogeneic Products	182
TABLE 13.6: Celregen's Key iPSC Product Candidates	185
TABLE 13.7: Cellectis' Main Product Candidates	186
TABLE 13.8: Celregen's Product Pipeline	193
TABLE 13.9: Century Therapeutics' Pipeline Overview	196
TABLE 13.10: Cynata's Clinical Pipeline	204
TABLE 13.11: Factor Bioscience's iPSC-Based Clinical Trials	214
TABLE 13.12: Fate Therapeutics' Pipeline Overview	215
TABLE 13.13: Gameto's Pipeline	218
TABLE 13.14: Greenstone's Pipeline	223
TABLE 13.15: Healios' Research and Development Status	224
TABLE 13.16: Hebecell's Pipelines	229
TABLE 13.17: HELP's R&D Pipeline	230
TABLE 13.18: Herophilus' Pipeline Development using Organoids	231
TABLE 13.19: Key Available Organoid Types with HUB	234
TABLE 13.20: iCamuno's Product Pipeline	235
TABLE 13.21: IPS HEART's Pipeline	242
TABLE 13.22: iPSirius' Pipeline	243
TABLE 13.23: iRegene's Pipelines	244
TABLE 13.24: Kenai's Pipeline	251
TABLE 13.25: Khloris' iPSC Product Development Stages and Diseases Addressed	251
TABLE 13.26: Kiji's R&D Pipeline	252
TABLE 13.27: Laverock's Pipeline.....	254
TABLE 13.28: Pipeline from Lineage Cell Therapeutics.....	255
TABLE 13.29: Megakaryon's R&D Pipeline.....	258
TABLE 13.30: Morphocell's Pipeline.....	261
TABLE 13.31: ReproCELL's Clinical Pipelines Currently under Development.....	285
TABLE 13.32: Ricoh's Therapeutics Development Pipeline	288
TABLE 13.33: Sana's Product Candidates	290
TABLE 13.34: Sumitomo's iPSC Products in Development	299
TABLE 13.35: Vanqua Bio's Pipeline.....	309
TABLE 13.36: Vascugen's Product Pipeline	310
TABLE 13.37: VCCT's Pipeline	311

About BioInformant:

Founded in 2006, BioInformant is the world's first and only market research firm to specialize in the stem cell industry. Headquartered near Washington, DC, to be situated near the U.S. FDA, NIH, Capitol Hill, and the Maryland Biotech Corridor, BioInformant has collected 20+ years of historical data on the stem cell industry, providing a robust and unusual foundation on which to base its market research.

To date, BioInformant research has been cited by the *Wall Street Journal* and *Vogue Magazine*, as well as quoted by Tony Robbins in his best-selling book, *LifeForce*.

BioInformant operates the world's largest stem cell industry news site, attracting nearly a million readers per year.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.

